TY - JOUR
T1 - Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection
T2 - Generic Protocol for a Test-Negative Case-Control Study
AU - Roekel, Caren Van
AU - Poukka, Eero
AU - Turunen, Topi
AU - Nohynek, Hanna
AU - Presser, Lance
AU - Meijer, Adam
AU - Heikkinen, Terho
AU - Kramer, Rolf
AU - Begier, Elizabeth
AU - Teirlinck, Anne C.
AU - Knol, Mirjam
AU - Nair, Harish
AU - Campbell, Harry
AU - Bont, Louis
AU - Meijer, Adam
AU - Gideonse, David
AU - Backx, Anoek
AU - Melker, Hester De
AU - Presser, Lance
AU - Turunen, Topi
AU - Nohynek, Hanna
AU - Poukka, Eero
AU - Saukkoriipi, Annika
AU - Paget, John
AU - Summeren, Jojanneke Van
AU - Dückers, Michel
AU - Heikkinen, Terho
AU - Audenis, Berta Gumí
AU - Llavero, Maica
AU - Kragten, Leyla
AU - Kriek, Lies
AU - Faksová, Kristýna
AU - Giardini, Michele
AU - Emborg, Hanne Dorthe
AU - Rocchi, Francesca
AU - Quiles, Cintia Muñoz
AU - Diez-Domingo, Javier
AU - Vernhes, Charlotte
AU - Demont, Clarisse
AU - Robin, Aurelie
AU - Neveu, David
AU - Marcelon, Lydie
AU - Bangert, Mathieu
AU - Kramer, Rolf
AU - Martyn, Oliver
AU - Bardone, Corinne
AU - Remy, Vanessa
N1 - Publisher Copyright:
© 2024 Oxford University Press. All rights reserved.
PY - 2024/3/15
Y1 - 2024/3/15
N2 - Monitoring the real-life effectiveness of respiratory syncytial virus (RSV) products is of major public health importance. This generic protocol for a test-negative design study aims to address currently envisioned approaches for RSV prevention (monoclonal antibodies and vaccines) to study effectiveness of these products among target groups: children, older adults, and pregnant women. The generic protocol approach was chosen to allow for flexibility in adapting the protocol to a specific setting. This protocol includes severe acute respiratory infection (SARI) and acute respiratory infection (ARI), both due to RSV, as end points. These end points can be applied to studies in hospitals, primarily targeting patients with more severe disease, but also to studies in general practitioner clinics targeting ARI.
AB - Monitoring the real-life effectiveness of respiratory syncytial virus (RSV) products is of major public health importance. This generic protocol for a test-negative design study aims to address currently envisioned approaches for RSV prevention (monoclonal antibodies and vaccines) to study effectiveness of these products among target groups: children, older adults, and pregnant women. The generic protocol approach was chosen to allow for flexibility in adapting the protocol to a specific setting. This protocol includes severe acute respiratory infection (SARI) and acute respiratory infection (ARI), both due to RSV, as end points. These end points can be applied to studies in hospitals, primarily targeting patients with more severe disease, but also to studies in general practitioner clinics targeting ARI.
KW - (severe) acute respiratory infection
KW - monoclonal antibody
KW - real-world effectiveness
KW - RSV
KW - test-negative design study
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85186577798&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiad483
DO - 10.1093/infdis/jiad483
M3 - Article
C2 - 37935046
AN - SCOPUS:85186577798
SN - 0022-1899
VL - 229
SP - S92-S99
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -